期刊
ACR OPEN RHEUMATOLOGY
卷 4, 期 8, 页码 658-670出版社
WILEY
DOI: 10.1002/acr2.11436
关键词
-
类别
资金
- Rheumatology Research foundation
- VA [CDA2 IK2CX001717]
- National Heart, Lung, and Blood Institute [R01-HL-123064]
- Myositis Association
- Pfizer
- Abbvie
- Octapharma
- Bristol Myers Squibb
This study compared the microbial composition between patients with dermatomyositis (DM) and healthy controls (HCs), and found that patients with DM, particularly those with interstitial lung disease (ILD)-associated myositis-specific autoantibodies (MSAs), have lower microbial diversity and a distinct taxonomic composition. Predictive metagenomics analysis also revealed functional alterations in multiple metabolic pathways, specifically those involved in lipopolysaccharide synthesis and transport.
Objective The study objective was to compare the microbial composition of patients with dermatomyositis (DM) and healthy controls (HCs) and determine whether microbial alterations are associated with clinical manifestations of DM. Methods The 16S ribosomal RNA gene sequencing was performed on fecal samples from patients with DM and HCs. Microbial composition and diversity were compared between subjects with DM and HCs and in association with several DM-specific clinical variables, including myositis-specific autoantibodies (MSAs). Differentially abundant microbial taxa and genes associated with clinical characteristics were identified, and functional analysis was performed using predicted metagenomics. Dietary intake was assessed using a 24-hour dietary recall. Results The fecal microbiome of 36 patients with DM and 26 HCs were analyzed. Patients with DM trended toward lower microbial diversity compared with HCs. The higher physician global damage score was significantly correlated with the lower microbial diversity in patients with DM. Patients with interstitial lung disease (ILD)-associated MSA (antisynthetase antibody (ab), anti-melanoma differentiation-associated protein 5 ab, n = 12) had significant differences in microbial composition and lower microbial diversity compared with HCs. Differential abundance testing demonstrated a unique taxonomic signature in the ILD-MSA subgroup, and predictive metagenomics identified functional alterations in a number of metabolic pathways. A significant increase in the relative abundance of Proteobacteria was positively correlated with multiple pathways involved in lipopolysaccharide synthesis and transport in the ILD-MSA group. Conclusion Patients with DM, particularly with ILD-associated MSAs, have lower microbial diversity and a distinct taxonomic composition compared with HCs. Further studies are needed to validate our findings and elucidate specific pathogenetic mechanisms that link the gut microbiome to clinical and pathological features of DM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据